Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
S0636: Erlotinib and Bevacizumab in Never-Smokers With Stage IIIB or Stage IV Primary Non-Small Cell Lung Cancer
NCT00445848 · View on ClinicalTrials.gov ↗
Study Summary
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab also may stop the growth of non-small cell lung cancer by blocking blood flow to the tumor. Giving erlotinib together with bevacizumab may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving erlotinib together with bevacizumab works in treating patients with stage IIIB or stage IV primary non-small cell lung cancer who have never smoked.
Conditions Studied
Interventions
- BIOLOGICAL bevacizumab
- DRUG erlotinib hydrochloride
Study Locations (20)
California
- Kaiser Permanente - Deer Valley — Antioch
- Alta Bates Summit Comprehensive Cancer Center — Berkeley
- Peninsula Medical Center — Burlingame
- Kaiser Permanente - Fremont — Fremont
- Marin Cancer Institute at Marin General Hospital — Greenbrae
- Kaiser Permanente Medical Center - Hayward — Hayward
- Tibotec Therapeutics - Division of Ortho Biotech Products, LP — Marysville
- Kaiser Permanente Medical Center - Oakland — Oakland
- Valley Medical Oncology Consultants - Pleasanton — Pleasanton
- Kaiser Permanente Medical Center - Redwood City — Redwood City
- Kaiser Permanente Medical Center - Richmond — Richmond
- Kaiser Permanente Medical Center - Roseville — Roseville
- University of California Davis Cancer Center — Sacramento
- South Sacramento Kaiser-Permanente Medical Center — Sacramento
- Kaiser Permanente Medical Center - Sacramento — Sacramento
- Kaiser Permanente Medical Center - San Francisco Geary Campus — San Francisco
- California Pacific Medical Center - California Campus — San Francisco
- Kaiser Permanente Medical Center - Santa Teresa — San Jose
- Kaiser Foundation Hospital - San Rafael — San Rafael
- Sutter Health - Western Division Cancer Research Group — San Rafael
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2007-07 |
| Est. Completion | 2014-01 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00445848
The ClinicalTrials.gov registry entry for NCT00445848 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 212 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 2 interventions — of which bevacizumab is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00445848 reports 20 study locations spanning 1 distinct geographic area — top geographies include California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00445848 about?
NCT00445848 is a clinical study titled "S0636: Erlotinib and Bevacizumab in Never-Smokers With Stage IIIB or Stage IV Primary Non-Small Cell Lung Cancer". RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them o...
What is the current status of trial NCT00445848?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 89 participants. The study started on 2007-07. Estimated completion is 2014-01.
What conditions does trial NCT00445848 study?
This clinical trial studies the following conditions: Lung Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00445848?
The interventions under investigation include: bevacizumab (BIOLOGICAL), erlotinib hydrochloride (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00445848?
This trial is sponsored by SWOG Cancer Research Network, which has 212 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00445848 being conducted?
This trial has 20 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.